Neural Therapeutics (FRA:M6B) Other Operating Expense: €0.05 Mil (TTM As of Jan. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Neural Therapeutics Other Operating Expense?

Neural Therapeutics FRA:M6B Other Operating Expense is €0.05 Mil as of Jan. 2026. The stock has 1 warning sign investors should review.

Neural Therapeutics's Other Operating Expense for the three months ended in Jan. 2026 was €0.02 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Jan. 2026 was €0.05 Mil.

Neural Therapeutics's quarterly Other Operating Expense declined from Jul. 2025 (€0.01 Mil) to Oct. 2025 (€0.01 Mil) but then increased from Oct. 2025 (€0.01 Mil) to Jan. 2026 (€0.02 Mil).

Neural Therapeutics's annual Other Operating Expense declined from Jul. 2023 (€0.00 Mil) to Jul. 2024 (€0.00 Mil) but then increased from Jul. 2024 (€0.00 Mil) to Jul. 2025 (€0.02 Mil).

Neural Therapeutics Other Operating Expense Historical Data

* Premium members only.

The historical data trend for Neural Therapeutics's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neural Therapeutics Other Operating Expense Chart

Neural Therapeutics Annual Data
Trend Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
Other Operating Expense
Get a 7-Day Free Trial 0.20 -0.00 0.00 0.00 0.02

Neural Therapeutics Quarterly Data
Jul20 Jul21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.01 0.01 0.01 0.02

Neural Therapeutics Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.05 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of €0.05 Mil mean?
Neural Therapeutics (FRA:M6B) has a Other Operating Expense of €0.05 Mil as of Jan. 2026. Other operating expenses that a company records on its income statement. View historical data on Neural Therapeutics and its competitors.
Is Neural Therapeutics' Other Operating Expense too high?
Neural Therapeutics' current Other Operating Expense is €0.05 Mil.
How does Neural Therapeutics' Other Operating Expense compare to VRTX and REGN?
Neural Therapeutics' Other Operating Expense of €0.05 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Neural Therapeutics and its competitors. Neural Therapeutics's current Other Operating Expense is €0.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neural Therapeutics stock overvalued right now?
Neural Therapeutics (FRA:M6B) has a current Other Operating Expense of €0.05 Mil. The current Other Operating Expense is €0.05 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Neural Therapeutics (FRA:M6B), the current Other Operating Expense is €0.05 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neural Therapeutics Business Description

Other Exchanges NURL:Canada
Address 1-130 Adelaide Street West, Suite 3002, Toronto, ON, CAN, M5H 3P5
Neural Therapeutics Inc is a wholly-owned subsidiary of High Fusion focused on ethnobotanical drug discovery and development company. Neural Therapeutics is focused on developing products and conducting research on the psychoactive cacti plants with the primary objective to find where the historical use in traditional medicine proves to be effective and capitalizing on the opportunities that can be applied in modern medical and natural health products markets.